Alexion Pharmaceuticals Inc. (ALXN)

114.29
2.76 2.36
NASDAQ : Health Technology
Prev Close 117.05
Open 115.28
Day Low/High 112.14 / 115.32
52 Wk Low/High 92.56 / 140.77
Volume 2.82M
Avg Volume 1.68M
Exchange NASDAQ
Shares Outstanding 223.10M
Market Cap 26.11B
EPS 2.00
P/E Ratio 25.56
Div & Yield N.A. (N.A)
Alexion Spikes Amid Report Activist Elliott Management Is Pushing for Change

Alexion Spikes Amid Report Activist Elliott Management Is Pushing for Change

A report says activist hedge fund Elliott Management wants plans to boost Alexion's share price or it will start a proxy fight for seats on the board.

Stock Futures Add to Gains After Solid November Jobs Report

Stock Futures Add to Gains After Solid November Jobs Report

Wall Street is looking at another bullish session Friday as the U.S. added 228,000 jobs to payrolls in November, higher than expected.

Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers

Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers

The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder.

Alexion And Halozyme Enter License Agreement For ENHANZE Technology

Alexion And Halozyme Enter License Agreement For ENHANZE Technology

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Halozyme Therapeutics, Inc.

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.

Alexion To Present At The Citi 2017 Global Healthcare Conference

Alexion To Present At The Citi 2017 Global Healthcare Conference

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at the Citi 2017 Global Healthcare Conference on Thursday, December 7, 2017 at 9:30 a.

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

There are a variety of players that should be active in the M&A space next year.

A Hamburger Chain, an Apparel Merchant and Other Stocks That Look Good Short

ALXN, FLWS, WEN, GPS and DIN all recently were downgraded by TheStreet's Quant Ratings.

Alexion Suffers Quantitative Downgrade, Bearish Charts

Alexion Suffers Quantitative Downgrade, Bearish Charts

The path of least resistance is downward for Alexion.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AVT, CAR, FF, WUBA Downgrades: ALXN, CLRO, DIN, JCAP, KLDX, MT, OTIV, SHEN, TGEN, THS, TREC Initiations: AIRG Read on to get TheStreet Quant Ratings' detailed report:

Alexion Appoints Francois Nader, M.D. To Its Board Of Directors

Alexion Appoints Francois Nader, M.D. To Its Board Of Directors

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Francois Nader, M.

Alexion Receives New Japanese Patent For Soliris® (eculizumab), Extending Patent Protection Into 2027 And Strengthening Global Patent Portfolio

Alexion Receives New Japanese Patent For Soliris® (eculizumab), Extending Patent Protection Into 2027 And Strengthening Global Patent Portfolio

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the Japanese Patent Office (JPO) has issued patent No.

New Interim Data Presented At NASPGHAN 2017 Meeting Show Survival Beyond 1 Year Of Age In Infants With LAL-D Treated With Kanuma® (sebelipase Alfa)

New Interim Data Presented At NASPGHAN 2017 Meeting Show Survival Beyond 1 Year Of Age In Infants With LAL-D Treated With Kanuma® (sebelipase Alfa)

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that new interim data show that 80% of infants (8 out of 10) with rapidly progressive lysosomal acid lipase deficiency (LAL-D) treated with Kanuma®...

New Phase 1/2 Study Data For ALXN1210 As A Potential Future Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) To Be Presented At American Society Of Hematology (ASH) Meeting

New Phase 1/2 Study Data For ALXN1210 As A Potential Future Treatment For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) To Be Presented At American Society Of Hematology (ASH) Meeting

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that researchers will present new data from two Phase 1/2 clinical studies of ALXN1210, the Company's investigational long-acting complement inhibitor, in...

Alexion To Present At The 26th Annual Credit Suisse Healthcare Conference

Alexion To Present At The 26th Annual Credit Suisse Healthcare Conference

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that management will present at the 26th Annual Credit Suisse Healthcare Conference in Scottsdale, AZ on Tuesday, November 7, 2017 at 10:20 a.

Celgene, Bristol-Myers Drop on Poor Earnings as Big Pharma Takes It on the Chin

Celgene, Bristol-Myers Drop on Poor Earnings as Big Pharma Takes It on the Chin

Alexion Pharmaceuticals, Bristol-Myers Squibb and Celgene were among the healthcare firms that unveiled quarterly numbers on Oct. 26.

Alexion Reports Third Quarter 2017 Results

Alexion Reports Third Quarter 2017 Results

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the third quarter of 2017.

Alexion Pharmaceuticals Stock Jumps on FDA Approval of Soliris

Alexion Pharmaceuticals Stock Jumps on FDA Approval of Soliris

The treatment is for adult patients with generalized myasthenia gravis (gMG).

Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers

Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers

The New Haven, Conn.-based firm said Monday it has secured approval from the U.S. Food and Drug Administration for Soliris (eculizumab) as a treatment for adults with generalized myasthenia gravis (gMG) that are anti-acetylcholine receptor (AChR) antibody-positive.

(Photo: Business Wire)

(Photo: Business Wire)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.

Alexion Pharmaceuticals Achieves #54 Analyst Rank, Surpassing Masco

Alexion Pharmaceuticals Achieves #54 Analyst Rank, Surpassing Masco

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Alexion Pharmaceuticals Inc. has taken over the #54 spot from Masco Corp.

Alexion To Report Third Quarter 2017 Results On Thursday, October 26, 2017

Alexion To Report Third Quarter 2017 Results On Thursday, October 26, 2017

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the third quarter 2017 on Thursday, October 26, 2017 before the US financial markets open.

Alexion Adds Paul A. Friedman, M.D. To Its Board Of Directors

Alexion Adds Paul A. Friedman, M.D. To Its Board Of Directors

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Paul A.

Interim Analysis From Phase 3 Open-Label Extension Study Shows Sustained Benefits Of Soliris® (Eculizumab) Treatment For Patients With Refractory Generalized Myasthenia Gravis

Interim Analysis From Phase 3 Open-Label Extension Study Shows Sustained Benefits Of Soliris® (Eculizumab) Treatment For Patients With Refractory Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today results from an interim analysis of an ongoing Phase 3 open-label extension study of the pivotal, placebo-controlled REGAIN study of Soliris ® (eculizumab)...

Alexion Could Target Sage, Ra Pharma: Analyst

Alexion Could Target Sage, Ra Pharma: Analyst

BMO Capital Markets analyst M. Ian Somaiya says Alexion could view Sage Therapeutics and Ra Pharmaceuticals as potential acquisition targets. Somaiya pointed to Sage's diverse pipeline and Ra's diversified complement pipeline.

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

The Dow, S&P 500 and Nasdaq score new records on Tuesday, Sept. 12, as the promise of tax reform fuels gains in the financials sector.

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Stocks returned to session highs as Apple Inc. lays out its latest product launches, including a new version of its smartwatch and iPhone. Here's where stocks are trading Tuesday afternoon.

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks edged higher in cautious gains after Monday's rally pulled the Dow Jones Industrial Average and S&P 500 to their best gains in six months.

TheStreet Quant Rating: C+ (Hold)